FDA Approves Soliris For Rare Pediatric Blood Disorder
The U.S. Food and Drug Administration today approved Soliris ( eculizumab ) to treat patients with atypical hemolytic uremic syndrome ( aHUS ), a rare and chronic blood disease that can lead to kidney (renal) failure and is also associated with increased risk of death and stroke.